Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -96.96% is 100% above its 5-year average of -30130.71%, near the high end of its 5-year range (-180128.57%–13.55%).
88.35% above its 12-month average of -832.59%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -3820.52%.
EBITDA MARGIN
-96.96%
EBITDA MARGIN AVG TTM
-832.59%
EBITDA MARGIN AVG 3Y
-2175.20%
EBITDA MARGIN AVG 5Y
-30130.71%
EBITDA MARGIN AVG 10Y
-1603.68%
EBITDA MARGIN AVG 15Y
-3551.26%
EBITDA MARGIN AVG 20Y
-2815.06%
CURRENT VS TTM AVG
+88.35%
CURRENT VS 3Y AVG
+95.54%
CURRENT VS 5Y AVG
+99.68%
CURRENT VS 10Y AVG
+93.95%
CURRENT VS 15Y AVG
+97.27%
CURRENT VS 20Y AVG
+96.56%
Lexicon Pharmaceuticals, Inc.
Market Cap
$779.56M
EBITDA Margin
-96.96%
TTM Avg
-832.59%
3Y Avg
-2175.20%
5Y Avg
-30130.71%
Market Cap
$780.99M
EBITDA Margin
-4915.19%
TTM Avg
-4915.19%
3Y Avg
-4915.19%
5Y Avg
-4915.19%
Market Cap
$771.14M
EBITDA Margin
16.77%
TTM Avg
16.87%
3Y Avg
-15.22%
5Y Avg
-3.72%
Market Cap
$789.58M
EBITDA Margin
-28.62%
TTM Avg
-126.34%
3Y Avg
-26187.68%
5Y Avg
-23869.36%
Market Cap
$797.41M
EBITDA Margin
18.47%
TTM Avg
18.88%
3Y Avg
13.21%
5Y Avg
14.52%
Market Cap
$759.48M
EBITDA Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$802.16M
EBITDA Margin
12.02%
TTM Avg
14.44%
3Y Avg
-4.83%
5Y Avg
-238.26%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexicon Pharmaceuticals, Inc. (LXRX) | $779.56M | -96.96% | -832.59% | -2175.20% | -30130.71% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $780.99M | -4915.19% | -4915.19% | -4915.19% | -4915.19% |
| Mesa Laboratories, Inc. (MLAB)vs › | $771.14M | 16.77% | 16.87% | -15.22% | -3.72% |
| Sana Biotechnology, Inc. (SANA)vs › | $788.07M | N/A | N/A | N/A | N/A |
| Geron Corporation (GERN)vs › | $789.58M | -28.62% | -126.34% | -26187.68% | -23869.36% |
| AdaptHealth Corp. (AHCO)vs › | $797.41M | 18.47% | 18.88% | 13.21% | 14.52% |
| Design Therapeutics, Inc. (DSGN)vs › | $759.48M | 0.00% | 0.00% | 0.00% | 0.00% |
| Apnimed, Inc. (APMD)vs › | $792.48M | N/A | N/A | N/A | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $802.16M | 12.02% | 14.44% | -4.83% | -238.26% |
| InMode Ltd. (INMD)vs › | $805.36M | 23.23% | 25.96% | 33.88% | 36.34% |
Gross Margin
98.8%
EBITDA Margin
-97.0%
Operating Margin
-98.2%
Net Margin
-147.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -3820.52% |
| 2026-03-31 | -4.20% |
| 2025-12-31 | -266.92% |
| 2025-09-30 | -84.87% |
| 2025-06-30 | 13.55% |
| 2025-03-31 | -2020.84% |
| 2024-12-31 | -122.81% |
| 2024-09-30 | -3632.40% |
| 2024-06-30 | -3352.46% |
| 2024-03-31 | -3999.03% |
| 2023-12-31 | -6636.75% |
| 2023-09-30 | -30543.21% |
| 2023-06-30 | -13910.41% |
| 2023-03-31 | -129291.67% |
| 2022-12-31 | -107767.86% |
| 2022-09-30 | -58941.03% |
| 2022-06-30 | -68285.71% |
| 2022-03-31 | -62894.59% |
| 2021-12-31 | -180128.57% |
| 2021-09-30 | -99395.65% |
| 2021-06-30 | -7656.84% |
| 2021-03-31 | -77044.44% |
| 2020-12-31 | -2971.86% |
| 2020-09-30 | 1318.34% |
| 2020-06-30 | -694.96% |
| 2020-03-31 | -769.25% |
| 2019-12-31 | -530.33% |
| 2019-09-30 | 76.61% |
| 2019-06-30 | -182.14% |
| 2019-03-31 | -179.77% |
| 2018-12-31 | -67.10% |
| 2018-09-30 | -322.71% |
| 2018-06-30 | -214.51% |
| 2018-03-31 | -146.95% |
| 2017-12-31 | -90.36% |
| 2017-09-30 | -106.14% |
| 2017-06-30 | -273.58% |
| 2017-03-31 | -228.78% |
| 2016-12-31 | -133.79% |
| 2016-09-30 | -124.19% |
| 2016-06-30 | -181.72% |
| 2016-03-31 | -266.93% |
| 2015-12-31 | 69.47% |
| 2015-09-30 | -5939.40% |
| 2015-06-30 | -7032.45% |
| 2015-03-31 | -1460.49% |
| 2014-12-31 | -15.10% |
| 2014-09-30 | -9501.19% |
| 2014-06-30 | -3780.62% |
| 2014-03-31 | -10768.23% |
| 2013-12-31 | -1156.52% |
| 2013-09-30 | -12873.95% |
| 2013-06-30 | -12990.19% |
| 2013-03-31 | -6878.33% |
| 2012-12-31 | -10814.68% |
| 2012-09-30 | -7528.23% |
| 2012-06-30 | -12254.27% |
| 2012-03-31 | -9419.33% |
| 2011-12-31 | -9389.80% |
| 2011-09-30 | -6904.23% |
| 2011-06-30 | -4443.60% |
| 2011-03-31 | -4669.30% |
| 2010-12-31 | -1685.00% |
| 2010-09-30 | -2934.19% |
| 2010-06-30 | -1841.77% |
| 2010-03-31 | -1437.29% |
| 2009-12-31 | -1448.16% |
| 2009-09-30 | -953.26% |
| 2009-06-30 | -710.51% |
| 2009-03-31 | -522.98% |
| 2008-12-31 | -265.76% |
| 2008-09-30 | -319.01% |
| 2008-06-30 | -248.59% |
| 2008-03-31 | -245.64% |
| 2007-12-31 | -109.96% |
| 2007-09-30 | -169.36% |
| 2007-06-30 | -122.57% |
| 2007-03-31 | -123.21% |
| 2006-12-31 | -74.67% |
| 2006-09-30 | -51.09% |
| 2006-06-30 | -86.45% |
| 2006-03-31 | -38.36% |
| 2005-12-31 | 25.50% |
| 2005-09-30 | -79.69% |
| 2005-06-30 | -83.51% |
| 2005-03-31 | -74.64% |
| 2004-12-31 | 6.58% |
| 2004-09-30 | -84.71% |
| 2004-06-30 | -125.60% |
| 2004-03-31 | -98.40% |
| 2003-12-31 | -50.99% |
| 2003-09-30 | -78.03% |
| 2003-06-30 | -139.86% |
| 2003-03-31 | -149.89% |
| 2002-12-31 | -90.56% |
| 2002-09-30 | -152.63% |
